9.12. Criteria to Pause Enrollment
Phase 2 Pivotal Study As part of its oversight of the study, the DSMB also will assess criteria to pause enrollment after 10, 20, 30, and 50 subjects in the Phase 2 pivotal portion of the study have been treated with axicabtagene ciloleucel and have had the opportunity to be followed for 30 days.  Enrollment will be paused if any of the following criteria is met: 1) Subject incidence of Grade 5 axicabtagene ciloleucel-related adverse events within 30 days is > 10%. or 2) Subject incidence of the following Grade 4 axicabtagene ciloleucel-related adverse events lasting more than 7 days is > 33%:  Neurologic toxicities  CRS (per Lee 2014 criteria) (Lee et al, 2014)  Other non-hematological serious adverse event  Infection (treatment-related)